June 5, 2018 — The U.S. Food and Drug Administration (FDA) has cleared the Biograph Vision, a new positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.
PET Imaging
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.
-
-
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and president-elect of the American Society of Nuclear Cardiology (ASNC), explained advances in PET and SPECT imaging and the learning curve involved in reading scans from the new CZT...
-
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that...
-
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging. The term was developed after thousands of autopsies, numerous discoveries and significant research linked asbestos to a deadly form of cancer.
-
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American Society of Nuclear Cardiology (ASNC), discusses advancements in nuclear imaging and some of the issues facing the subspecialty.
News | PET Imaging | September 05, 2018
September 5, 2018 — Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of...
Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.
News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study...
News | PET Imaging | July 17, 2018
July 17, 2018 — A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new...
Technology | Nuclear Imaging | July 16, 2018
July 16, 2018 — At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23...
IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.
68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.
News | PET Imaging | June 29, 2018
June 29, 2018 — In the battle against metastatic castrate-resistant...
Technology | PET Imaging | June 28, 2018
June 28, 2018 — At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in...
News | PET Imaging | June 25, 2018
June 25, 2018 — IMV, part of the Science and Medicine Group and a market research and business intelligence provider...
Technology | PET-CT | June 21, 2018
June 21, 2018 — Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new...
News | Prostate Cancer | June 13, 2018
June 13, 2018 — A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine...
Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.
Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S. Food and Drug Administration (FDA) has cleared the Biograph Vision, a new...
News | Computed Tomography (CT) | May 21, 2018
May 21, 2018 — The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation...
Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea
News | PET Imaging | May 17, 2018
May 17, 2018 — A novel positron emission...
News | PET Imaging | May 11, 2018
May 11, 2018 — A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics Acquires Worldwide Rights to Investigational Radiohybrid PSMA-Targeted Agents
May 9, 2018 — Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a...
Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland
News | PET Imaging | April 10, 2018
April 10, 2018 — Researchers have developed a new imaging agent that could help guide and assess treatments for...
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.
News | Prostate Cancer | March 07, 2018
An Italian study featured in the March...
News | PET Imaging | February 21, 2018
February 21, 2018 — Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the...
